Prognostic Factors for Survival in Patients With Unresectable Pancreatic Cancer

Pancreas ◽  
2010 ◽  
Vol 39 (8) ◽  
pp. 1247-1253 ◽  
Author(s):  
Andreas Weber ◽  
Victoria Kehl ◽  
Tobias Mittermeyer ◽  
Esther Herberich ◽  
Nadine Röthling ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Unresectable Pancreatic Cancer

scholarly journals Prognostic Factors in Patients with Unresectable Pancreatic Cancer Treated with Gemcitabine: A Retrospective Analysis

2014 ◽  
Vol 40 (12) ◽  
pp. 734-741 ◽  
Author(s):  
Masahiro Hatori ◽  
Daiki Tsuji ◽  
Keisei Taku ◽  
Takashi Daimon ◽  
Mana Kamezato ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Retrospective Analysis ◽  
Unresectable Pancreatic Cancer

Survival and Prognostic Factors of Unresectable Pancreatic Cancer

2008 ◽  
Vol 42 (1) ◽  
pp. 86-91 ◽  
Author(s):  
Joo Kyung Park ◽  
Yong Bum Yoon ◽  
Yong-Tae Kim ◽  
Ji Kon Ryu ◽  
Won Jae Yoon ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Unresectable Pancreatic Cancer

scholarly journals Prognostic factors in patients with unresectable pancreatic cancer

Suizo ◽  
2016 ◽  
Vol 31 (4) ◽  
pp. 631-637
Author(s):  
Makoto KADOKURA ◽  
Yasuaki ISHIDA ◽  
Akihisa TATSUMI ◽  
Ei TAKAHASHI ◽  
Hiroko SHINDO ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Unresectable Pancreatic Cancer

Optimal indications for chemotherapy in elderly patients with unresectable pancreatic cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 450-450
Author(s):  
Shoichi Nakazuru ◽  
Shoji Nakamori ◽  
Seiya Kato ◽  
Ayaka Shoji ◽  
Ryosuke Kiyota ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Elderly Patients ◽  
Performance Status ◽  
Univariate Analysis ◽  
Locally Advanced ◽  
Ct Scans ◽  
Unresectable Pancreatic Cancer ◽  
Cox Regression Analysis ◽  
Ecog Ps

450 Background: Pancreatic cancer is seen predominantly in elderly patients. Since many patients with pancreatic cancer have locally advanced unresectable tumors or distant metastases at diagnosis, they require chemotherapy. However, it is difficult to appropriately select elderly patients who are likely to benefit from chemotherapy. This study aimed to identify prognostic factors for elderly patients with unresectable pancreatic cancer treated with chemotherapy. Methods: We retrospectively analyzed the data of 191 patients with pancreatic cancer, aged ≥ 70 years, who had been diagnosed at our hospital between January 2006 and August 2016. Their overall survival (OS) was calculated using Kaplan-Meyer analysis. Prognostic factors were evaluated using Cox regression analysis. Results: Of the 191 patients, 52 patients with unresectable pancreatic cancer were treated with chemotherapy. Their median age was 76.5 years (range, 70–85 years). Twenty-two patients (42%) were men, and 44 (85%) had metastatic disease. Forty-one (79%) and 11 (21%) patients had ECOG performance status (PS) 0–1 and 2–3, respectively. Thirty-eight (73%), 10 (19%), and 4 (8%) patients received gemcitabine, gemcitabine-based combination regimens, and S-1, respectively, as first-line chemotherapy. The median OS was 219 days (range, 7–920 days). On univariate analysis, ECOG PS ≥ 2 (hazard ratio [HR], 4.37; P = 0.0005), carcinoembryonic antigen ≥ 10 ng/mL (HR, 2.32; P = 0.0162), serum AST ≥ 30 U/L (HR, 2.02; P = 0.0263), serum albumin < 3.0 g/dL (HR, 2.38; P = 0.0247), serum C-reactive protein ≥ 0.5 mg/dL (HR, 2.21; P = 0.0140), neutrophil-to-lymphocyte ratio ≥ 5.0 (HR, 3.25; P = 0.0066), and presence of ascites on computed tomography (CT) scans (HR, 3.02; P = 0.0016) were significantly associated with shorter survival times. On multivariate analysis, ECOG PS ≥ 2 (HR, 5.49; 95% confidence interval [CI], 2.18–13.32; P = 0.0005) and presence of ascites on CT scans (HR, 2.53; 95% CI, 1.20–5.24; P = 0.0148) were associated with poor OS. Conclusions: Elderly patients with unresectable pancreatic cancer who have a good performance status and do not show ascites on CT scans are likely to benefit from chemotherapy.

scholarly journals Prognostic factors in patients with unresectable pancreatic cancer

2016 ◽  
Vol 27 ◽  
pp. vii91
Author(s):  
Makoto Kadokura ◽  
Takeshi Ishida ◽  
Naruki Shimamura ◽  
Akihisa Tatsumi ◽  
Fumitake Amemiya
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Unresectable Pancreatic Cancer

scholarly journals Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Naoto Iwai ◽  
Takashi Okuda ◽  
Junichi Sakagami ◽  
Taishi Harada ◽  
Tomoya Ohara ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Group Performance ◽  
Prognostic Score ◽  
Neutrophil To Lymphocyte Ratio ◽  
Metastatic Pancreatic Cancer ◽  
Unresectable Pancreatic Cancer ◽  
Characteristic Analysis ◽  
Lymphocyte Ratio ◽  
Ecog Ps

Abstract Inflammation-based prognostic indicators have been developed to predict the prognosis in patients with pancreatic cancer. However, prognostic indices have not been established in patients with unresectable pancreatic cancer, including those without indication for chemotherapy at diagnosis. This study aimed to identify the predictors in all patients with unresectable pancreatic cancer. We retrospectively analyzed data of 119 patients with unresectable pancreatic cancer from June 2006 to September 2018. The following laboratory parameters were evaluated: the Glasgow Prognostic Score (GPS), modified GPS, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein albumin (CRP/Alb) ratio, and prognostic nutritional index (PNI). We performed time-dependent receiver operating characteristic analysis, overall survival (OS) analysis, and univariate and multivariate analyses to determine the prognostic factors in patients with unresectable pancreatic cancer. The cut-off value for NLR was determined to be 3.74. The 6-month OS rates in low and high NLR groups were 75.5% and 18.8% (P < 0.001). In the univariate analysis, advanced age (P = 0.003), metastatic pancreatic cancer (P = 0.037), no treatment (P < 0.001), worse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) (P < 0.001), high GPS (P < 0.001), high modified GPS (P < 0.001), high NLR (P < 0.001), high PLR (P = 0.002), high CRP/Alb ratio (P < 0.001), and low PNI (P < 0.001) were identified as the prognostic factors. The multivariate analysis revealed that metastatic pancreatic cancer (P = 0.046), no treatment (P < 0.001), worse ECOG-PS (P = 0.002), and high NLR (P < 0.001) were independently associated with OS. We revealed that the high NLR could be an independent indicator of poor prognosis in patients with unresectable pancreatic cancer.

Prognostic implication of intraoperative radiotherapy for unresectable pancreatic cancer.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 346-346
Author(s):  
T. Fujii ◽  
S. Nagai ◽  
Y. Kodera ◽  
M. Kanda ◽  
T. T. Sahin ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Liver Metastasis ◽  
Peritoneal Metastasis ◽  
Locally Advanced ◽  
Intraoperative Radiotherapy ◽  
Disease Spread ◽  
Unresectable Pancreatic Cancer ◽  
Peritoneal Disease

346 Background: There is no established treatment strategy for unresectable pancreatic cancer, and the prognostic effect of intraoperative radiotherapy (IORT) is considered to be limited. Methods: We reviewed 614 surgical cases of pancreatic cancer and selected 198 cases that did not undergo pancreatectomy because of distant metastasis or locally advanced disease, at the Department of Surgery II, between July 1981 and June 2009. Liver metastasis was observed in 70 patients and peritoneal metastasis in 44. Treatment for those who were feasible consisted of IORT and/or postoperative chemotherapy. Overall survival and prognostic factors were evaluated for all patients and for each pattern of disease spread. Results: IORT was performed in 120 patients (61%), and chemotherapy was indicated in 80 (40%). Overall survival in the non-treatment group was significantly inferior to that for IORT alone and IORT plus gemcitabine (GEM)-based chemotherapy (median survival time: 3.2 months vs. 6.1 and 7.9 months; P = 0.0001 and <0.0001, respectively). After multivariate analysis, IORT and GEM-based chemotherapy were identified as independent prognostic factors [hazard ratio (HR) = 0.51, P < 0.001; HR = 0.43, P < 0.001]. IORT was an independent prognostic determinant for patients with peritoneal metastasis (HR = 0.24, P = 0.011), whereas it was not for those with liver metastasis (HR = 0.78, P = 0.381). Conclusions: The prognostic value of IORT is most prominent in the peritoneal disease. IORT followed by GEM-based chemotherapy is possibly one of the most recommended treatment strategies in unresectable pancreatic cancer. No significant financial relationships to disclose.

Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer

2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Ulla Klaiber ◽  
Eva S. Schnaidt ◽  
Ulf Hinz ◽  
Matthias M. Gaida ◽  
Ulrike Heger ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Neoadjuvant Treatment ◽  
Unresectable Pancreatic Cancer
Sign in / Sign up

Export Citation Format

Share Document